Mesoblast Limited (AU:MSB) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Mesoblast Limited has received FDA approval for Ryoncil, making it the first mesenchymal stromal cell therapy approved in the U.S. for treating steroid-refractory acute graft versus host disease in children. This groundbreaking approval positions Ryoncil as a vital treatment option for a condition with limited alternatives and high mortality rates. With promising trial results, Mesoblast aims to extend Ryoncil’s application to other inflammatory conditions.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
